MediGene AG Submits New Drug Application for Polyphenon® E Ointment for the Treatment of Genital Warts

29.09.2005

MediGene AG announced that it has submitted an NDA for its Polyphenon® E Ointment for the treatment of genital warts to the US FDA (Food and Drug Administration). MediGene owns the worldwide marketing rights for the drug and is planning submission for marketing authorization in Europe next year.

"Reaching this stage for our second drug represents a major success for MediGene. This again illustrates our expertise in bringing drugs from the early stages to the market," said Dr. Peter Heinrich, Chief Executive Officer of MediGene AG. "We are planning for the US market launch of Polyphenon® E Ointment in 2007 along with a marketing and commercialization partner followed by commercialization in Europe."

Weitere News aus dem Ressort Forschung & Entwicklung

Meistgelesene News

Weitere News von unseren anderen Portalen

Kampf gegen Krebs: Neueste Entwicklungen und Fortschritte